This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary c-Met/HGFR Therapeutic Antibody Development
BioVenic provides veterinary c-Met/HGFR therapeutic antibody development services to drive advances in companion animal healthcare. We have built a versatile platform for developing veterinary therapeutic antibodies and adopt innovative antibody preparation and optimization technologies to deliver high-quality research services. The c-Met/HGFR molecule is a prominent research target in oncology, and antibody development targeting this target carries promising therapeutic value for companion animals affected by related disorders.
Background of c-Met/HGFR
| Full Name | c-Mesenchymal-epithelial transition factor/Hepatocyte growth factor receptor |
|---|---|
| Aliases | AUTS9, DA11, DFNB97, MET, RCCP2. |
| Target Profile | As a tyrosine kinase receptor, c-Met/HGFR consists of three structural domains: an extracellular region, a transmembrane domain, and an intracellular region. It is primarily expressed on the cell surface, and its ligand is hepatocyte growth factor (HGF), playing a crucial role in both normal tissue development and tumor progression. |
MoA of c-Met/HGFR
The primary ligand for c-Met is the hepatocyte growth factor (HGF). HGF, a member of the soluble cytokine family, activates the HGF/c-Met signaling through a paracrine mechanism, subsequently triggering a series of downstream signaling pathways such as RAS/MAPK and PI3K/AKT to exert its biological functions. Under normal physiological conditions, the binding of HGF to c-Met can induce tyrosine phosphorylation, promoting cell proliferation, growth, migration, differentiation, and tissue repair effects. When the regulation of the c-Met pathway is abnormal, such as through overexpression, it may initiate the transformation of normal cells into tumor cells, promote tumor cell proliferation and metastasis, and further drive their invasion, metastasis, and spread.
Fig.1 Schematic diagram of HGF/c-Met pathways.1,2
Application in Veterinary Therapeutics
c-Met/HGFR can play a significant role in the treatment of tumors in companion animals. The increase in c-Met/HGFR is a negative prognostic factor, as it can lead to an increase in the malignancy of tumors. For canine mammary tumors, c-Met/HGFR exhibits complex overexpression and dysregulation. Therefore, c-Met/HGFR can be a potential target for the treatment of canine mammary tumors. The development of veterinary c-Met/HGFR therapeutic antibodies aimed at inhibiting its overexpression can reduce its impact on tumor cell proliferation and metastasis.
Veterinary c-Met/HGFR Therapeutic Antibody Development Services
Numerous cancer treatment research projects focusing on c-Met/HGFR are currently underway. To support research targeting this marker in companion animals such as canines, felines, and equines, Biovenic offers veterinary c-Met/HGFR therapeutic antibody development services. Our services encompass every stage from antibody design and characterization to engineering optimization, fully meeting development needs and ensuring the antibodies are optimally suited for therapeutic research in companion animals.
To learn more about our c-Met/HGFR therapeutic antibody development services, please click the link below.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
A wide range of veterinary therapeutic antibody development technologies is available for your selection.
We offer antibody characterization services to ensure the quality of veterinary therapeutic antibodies, including sterility testing and purity analysis as part of our quality control measures.
We provide species-specific antibody development services, while also maintaining high antibody affinity to ensure therapeutic effectiveness.
Frequently Asked Questions
What pathological changes occur when the c-Met/HGFR signaling pathway is abnormally activated in companion animals?
Excessive activation or overexpression of the c-Met/HGFR pathway triggers continuous activation of downstream RAS/MAPK and PI3K/AKT cascades, which drives abnormal proliferation, invasion and distant metastasis of tumor cells. This marker is highly overexpressed in canine mammary tumors and serves as a negative indicator of tumor prognosis.
How do anti-c-Met therapeutic antibodies exert anti-tumor therapeutic effects on companion animals?
Therapeutic antibodies specifically bind to the extracellular domain of c-Met receptor on tumor cell surfaces, blocking the binding between HGF ligand and receptor. This cuts off downstream oncogenic signal transduction, thereby suppressing tumor cell proliferation, migration and invasive capacity to slow tumor progression and metastasis in pets such as dogs and cats.
What antibody screening platforms can be used to develop companion animal-specific anti-c-Met antibodies?
We offer four mature antibody discovery pipelines: mouse hybridoma technology, single B cell sorting from canine/feline peripheral blood, phage display biopanning library screening, and transgenic mouse hybridoma systems. Post-screening, we carry out caninization/felinization modification to reduce in vivo immunogenicity.
What species-adaptive antibody optimization services do you provide for c-Met targeted therapy research?
We conduct CDR grafting, chimeric antibody construction and fully canine/feline antibody transformation for murine primary antibodies. While lowering heterologous protein components to avoid immune rejection in pets, we retain high target binding affinity to guarantee stable in vivo neutralization efficacy.
What complete quality control tests are included in our c-Met antibody characterization service?
After antibody construction and expression, we implement full quality inspection covering target binding affinity detection, purity analysis, sterility testing and functional pathway inhibition verification, delivering standardized qualified antibody samples for pet tumor preclinical research.
Partner with BioVenic
Dysregulation in the c-Met/HGFR pathway in oncology can be manifested through genetic mutations, amplification, rearrangement, or overexpression of proteins. Blocking the HGF/c-Met signaling pathway may effectively inhibit the occurrence, progression, and metastasis of tumors. BioVenic offers veterinary c-Met/HGFR therapeutic antibody development services to assist you in exploring tumor treatments in companion animals such as canine, feline, and equine. If you have needs in this area, please do not hesitate to contact us now.
References
- Zhang, Hongli, et al., "HGF/c-MET: a promising therapeutic target in the digestive system cancers." International journal of molecular sciences 19.11 (2018): 3295.
- Image retrieved from Figure 2 "The schematic diagram of c-mesenchymal–epithelial transition (c-MET) activation signaling pathways.", Zhang, Hongli, et al., 2018, used under [CC BY 4.0], the image title was changed to "Schematic diagram of HGF/c-Met pathways."